Yuichiro Matsuoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuichiro Matsuoka has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Nakayama
Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
3 shared publications - Ryoji Yoshida
Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
3 shared publications - Akimitsu Hiraki
Department of Oral and Maxillofacial Surgery Fukuoka Dental College Fukuoka Japan
2 shared publications - Akiyuki Hirosue
Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
2 shared publications - Hidetaka Arita
Department of Oral and Maxillofacial Surgery Faculty of Life Sciences Kumamoto University Kumamoto Japan
2 shared publications - Junichiro Ishioka
Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 12 April 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 102 (8) , 896-907
The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation
- 12 April 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 102 (8) , 896-907
Open AccessThe antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation
- 20 October 2020
- Published by Wiley in Oral Diseases
- Vol. 27 (6) , 1564-1571
Role of serum amylase and salivary cytokines in oral complications during chemoradiotherapy
Objectives: To investigate whether serum amylase can predict the recovery of salivary volume and determine the correlation of the level of cytokines, including epidermal growth factor, hepatocyte growth factor and keratinocyte growth factor, with oral mucositis during chemoradiotherapy for oral cancer.Subjects and Methods: This study included 84 patients treated with preoperative chemoradiotherapy followed by curative surgery, following a phase II study protocol. We measured and analysed the correlation of the stimulated saliva volume, serum amylase and cytokines in resting saliva at baseline and 1 month after chemoradiotherapy with oral mucositis levels.Results: We observed a negative correlation between the serum amylase level at the beginning of chemoradiotherapy and the stimulated saliva volume at 1 month after chemoradiotherapy (p = .03). Epidermal growth factor in resting saliva was significantly reduced after chemoradiotherapy (p < .01). The incidence of severe oral mucositis during chemoradiotherapy was significantly higher and negatively associated with the epidermal growth factor and keratinocyte growth factor levels (p = .04, p = .05).Conclusions: The serum amylase level at the beginning of chemoradiotherapy may be a predictor of the recovery of the saliva volume. Furthermore, cytokines such as epidermal growth factor and keratinocyte growth factor in resting saliva affect the development of oral mucositis during chemoradiotherapy.
- 20 October 2020
- Published by Wiley in Oral Diseases
- Vol. 27 (6) , 1564-1571
Role of serum amylase and salivary cytokines in oral complications during chemoradiotherapy
Objectives: To investigate whether serum amylase can predict the recovery of salivary volume and determine the correlation of the level of cytokines, including epidermal growth factor, hepatocyte growth factor and keratinocyte growth factor, with oral mucositis during chemoradiotherapy for oral cancer.Subjects and Methods: This study included 84 patients treated with preoperative chemoradiotherapy followed by curative surgery, following a phase II study protocol. We measured and analysed the correlation of the stimulated saliva volume, serum amylase and cytokines in resting saliva at baseline and 1 month after chemoradiotherapy with oral mucositis levels.Results: We observed a negative correlation between the serum amylase level at the beginning of chemoradiotherapy and the stimulated saliva volume at 1 month after chemoradiotherapy (p = .03). Epidermal growth factor in resting saliva was significantly reduced after chemoradiotherapy (p < .01). The incidence of severe oral mucositis during chemoradiotherapy was significantly higher and negatively associated with the epidermal growth factor and keratinocyte growth factor levels (p = .04, p = .05).Conclusions: The serum amylase level at the beginning of chemoradiotherapy may be a predictor of the recovery of the saliva volume. Furthermore, cytokines such as epidermal growth factor and keratinocyte growth factor in resting saliva affect the development of oral mucositis during chemoradiotherapy.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1926-e1927
Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted MRI
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1926-e1927
Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted MRI
- Open Access
- 21 April 2017
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 6 (6) , 886-892
Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report
Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes. Radical resection of the tumor and submandibular gland with neck dissection were performed. One month after radical surgery, computed tomography (CT) scans indicated metastasis in the lower lobe of the left lung. CT-guided transthoracic fine-needle aspiration biopsy revealed a single metastasis and lung metastasectomy was immediately performed. The tumor cells of the primary lesion and those of the lung metastasis were immunohistochemically positive for epidermal growth factor receptor. One month later, multiple right lung metastases appeared, and the patient was treated with cisplatin/5-fluorouracil (5-FU) chemotherapy plus cetuximab, achieving a complete radiographic response. However, multiple lung metastases developed during adjuvant weekly cetuximab monotherapy. Subsequently, treatment with S-1 and weekly cetuximab was initiated, and the multiple lung metastases have been maintained as stable disease for 5 months. To the best of our knowledge, this is the first report of cetuximab use for the treatment of salivary duct carcinoma. Although cisplatin/5-FU chemotherapy plus cetuximab was efficacious in treating the lung metastasis, cetuximab monotherapy was insufficient for controlling tumor growth.
- 21 April 2017
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 6 (6) , 886-892
Open AccessSalivary duct carcinoma treated with cetuximab-based targeted therapy: A case report
Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes. Radical resection of the tumor and submandibular gland with neck dissection were performed. One month after radical surgery, computed tomography (CT) scans indicated metastasis in the lower lobe of the left lung. CT-guided transthoracic fine-needle aspiration biopsy revealed a single metastasis and lung metastasectomy was immediately performed. The tumor cells of the primary lesion and those of the lung metastasis were immunohistochemically positive for epidermal growth factor receptor. One month later, multiple right lung metastases appeared, and the patient was treated with cisplatin/5-fluorouracil (5-FU) chemotherapy plus cetuximab, achieving a complete radiographic response. However, multiple lung metastases developed during adjuvant weekly cetuximab monotherapy. Subsequently, treatment with S-1 and weekly cetuximab was initiated, and the multiple lung metastases have been maintained as stable disease for 5 months. To the best of our knowledge, this is the first report of cetuximab use for the treatment of salivary duct carcinoma. Although cisplatin/5-FU chemotherapy plus cetuximab was efficacious in treating the lung metastasis, cetuximab monotherapy was insufficient for controlling tumor growth.
- 20 March 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e983-e983b
983 A novel three-dimensional image display system for transurethral surgery
- 20 March 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e983-e983b
983 A novel three-dimensional image display system for transurethral surgery
- 1 December 2007
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 15, C178-C179
320 CARTILAGE T2 RELAXATION TIME UNDER LOADING CONDITION IN PATIENTS WITH NORMAL AND INJURED KNEE JOINTS
- 1 December 2007
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 15, C178-C179
320 CARTILAGE T2 RELAXATION TIME UNDER LOADING CONDITION IN PATIENTS WITH NORMAL AND INJURED KNEE JOINTS